Why Novo Nordisk A/S’s (NVO) Stock Is Down 6.85%
As of Monday, September 21, Novo Nordisk A/S’s NVO share price has dipped by 6.85%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Commentary & Analysis
Why Novo Nordisk A/S’s (NVO) Stock Is Down 9.15%
As of Friday, July 31, Novo Nordisk A/S’s NVO share price has dipped by 9.15%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Is Novo Nordisk A/S (NVO) Overvalued?
We dive into why Novo Nordisk A/S (NVO) could be considered overvalued on 2026-07-14, based on AAII’s Value Score and Grade.Rosalio Madrigal
Is Novo Nordisk A/S (NVO) Overvalued?
We dive into why Novo Nordisk A/S (NVO) could be considered overvalued on 2026-07-13, based on AAII’s Value Score and Grade.Jenna Brashear
Is Novo Nordisk A/S (NVO) Overvalued?
We dive into why Novo Nordisk A/S (NVO) could be considered overvalued on 2026-07-10, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | NVO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $167,770.4 | $498.4 | 98% |
|
| Shares Out (Mil) | 677.8 | 42.8 | 91% |
|
| Institutional Ownership | 99.9% | 81.2% | 96% |
|
| Float (Mil) | 3,168.4 | 44.5 | 97% |
|
| Beta | 0.35 | 0.72 | 20% |
|
| Avg Daily Volume (000s) | 9,303 | 264 | 96% |
|
| Price Change (52-week) |
(27.6%) | 56.1% | 32% |
|
| Growth | NVO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 18.4% | 6.4% | 79% |
|
| Net Income (5yr) | 18.4% | (2.0%) | 70% |
|
| EPS (5yr) | 19.6% | 15.0% | 68 |
|
| Dividends (5yr) | 19.7% | 0.0% | 88% |
|
| Cash Flow (5yr) | 41.0% | (15.1%) | 91% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 8 | 7 | |
| Current EPS | $0.689 | $3.339 | $3.414 | |
| Month Ago EPS | $0.746 | $3.393 | $3.287 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.728 | $3.246 | $3.207 | |
| Year/Year Chg | (4.7%) | (7.8%) | (0.2%) | |
| Financials | NVO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $50,341 | $416 | 97% |
|
| Net Income (TTM) (Mil) | $17,794 | ($11) | 99% |
|
| EPS (TTM) | $4.007 | ($0.700) | 83% |
|
| Operating Cash Flow (TTM) (Mil) | $20,153 | ($7) | 99% |
|
| Net Cash Flow (TTM) (Mil) | $4,006 | $3 | 99% |
|
| Long-Term Debt (Q1) (Mil) | $18,612 | $6 | 95% |
|
| Enterprise Value (Q1) (Mil) | $222,434 | $493 | 99% |
|
| Valuation | NVO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.01 | 2.16 | 80% |
|
| P/E | 9.6 | 17.4 | 16% |
|
| Dividend Yield | 3.0% | 0.0% | 84% |
|
| PEG (5yr hist) | 0.5 | 1.2 | 24% |
|
| Ratios | NVO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 82.0% | 69.4% | 90% |
|
| Net Margin | 35.3% | 3.3% | 92% |
|
| ROA | 21.3% | (21.8%) | 97% |
|
| ROE | 59.0% | (20.2%) | 94% |
|
| Liabilities to Assets | 62.8% | 32.0% | 57% |
|
| F-Score | 6 | 3 | 68% |
|
Passing Stock Screens
As of 10/28/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
O'Shaughnessy: Value Screen
Factors: Yield, Value
Value screen created by James O'Shaughnessy based on his study of a wide range of value approaches.
| Performance Since Inception: | 7.4% |
| +/- S&P 500: | -0.1 |
